1Elevan Biopharmaceuticals Announces the Development of Its Next-Generation Peptide Therapeutics Headquarters in Fishers, Indiana

The new 133,500-square-foot headquarters at 12001 Exit 5 Parkway will house an advanced pharmacy featuring category III, 503A/503B compounding capabilities alongside integrated telemedicine services for peptide therapy management and prescription fulfillment.

← Previous
Next →
  • ABOUT
    • EDITORIAL
    • SUBMIT PRESS RELEASES
  • ADVERTISE
  • CONTACT
  • PRIVACY
    • COOKIE POLICY
  • ABOUT
    • EDITORIAL
    • SUBMIT PRESS RELEASES
  • ADVERTISE
  • CONTACT
  • PRIVACY
    • COOKIE POLICY

© 2026 All rights Reserved. Medical Device News Magazine, is a Division of PTM Healthcare Marketing, Inc.